Medpal AI PLC - July Trading Update
MedPal AI plc
("MedPal", the "Company" or the "Group")
July Trading Update: Record Month Across All Three Revenue Streams
Group annualised recurring revenue run rate now over
MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy group, is pleased to provide a trading update for
Highlights
- From zero to
- NHS Prescriptions: record month. 47,223 NHS prescription items dispensed in
- Private Prescriptions: over
- SaaS revenue: approximately
- All revenue is repeat revenue. None of the Group's revenue streams is one-off in nature. NHS prescription revenues arise from repeat monthly prescriptions under long-term patient nominations, private prescription revenues arise from monthly repeat GLP-1 treatment plans and SaaS revenues arise from recurring monthly software subscriptions. The Board therefore regards the Group's revenue base as annualised recurring revenue.
- Cross-selling and upselling to accelerate growth further. The Group will cross-sell its NHS prescription service to New Health private patients, inviting them to nominate the Group's pharmacy for their everyday GP prescriptions, and will upsell the Group's wider services, including at-home blood testing, the MedPal Health OS app and Juno, its agentic AI health companion, across its entire client base. The Directors expect this to accelerate revenue growth even further, with each customer supporting multiple recurring revenue streams.
Final Settlement of eMARx acquisition
Further to the Company's announcement, on
Issue of
The Company has issued 928,570 new ordinary shares ("
The
Application will be made to the London Stock Exchange for the Fee Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and dealings in the Fee Shares will commence at
Following Admission, the Company's issued ordinary share capital will consist of 778,042,430 ordinary shares of
Chief Executive Officer's Commentary
"We are delighted to report further growth in monthly revenues for the Group, which have gone from zero to
"We commenced marketing of the New Health brand only three weeks ago and have further levers we intend to utilise; cross-selling NHS prescriptions to our private patients and upselling our wider services across the whole client base. Individual customers frequently generate multiple recurring revenue streams. We are just getting started."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic
For further information visit www.medpalai.com or contact the following:
Enquiries:
|
MedPal AI plc
|
Via Square1 Consulting |
|
Cairn Financial Advisers LLP (Nominated Adviser)
|
+44 (0) 20 7213 0880 |
|
Oak Securities (a trading name of Merlin Partners LLP) (Joint Broker)
|
+44 (0) 20 3973 3678 |
|
Clear Capital Markets Limited (Joint Broker)
|
+44 (0) 20 3869 6080 |
About MedPal AI plc
MedPal AI plc (AIM: MPAL; FRA: Z1N) is a vertically integrated, AI-native digital health and pharmacy group. The Group operates NHS Distance Selling Pharmacy hubs at Sarus Court,
Forward Looking Statements
This announcement contains forward-looking statements, which are based on the Company's current expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. Forward-looking statements are often identified by words such as "believes", "expects", "intends", "may", "will", "should", "could", "plans", "targets", "aims" or similar expressions. Such statements are subject to risks, assumptions and uncertainties and actual results, performance or events may differ materially from those expressed or implied by them. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law, the AIM Rules for Companies, the
END
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE